Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Beijing, Xicheng District, China Clinical Trials

A listing of Beijing, Xicheng District, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (48) clinical trials

Safety Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC.Biomarkers related to the efficacy of BPI-9016M will be investigated.

Phase

0.49 miles

Learn More »

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer NK Cells

This study will analyze and evaluate the following items: The safety of natural killerNK cells for treatment of subjects with solid tumors. Forty patients will be enrolled for each of the five cancers (in total 200 patients will be enrolled). The effectiveness of natural killerNKcell therapy alone or with chemotherapy ...

Phase

1.68 miles

Learn More »

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.

Phase

2.13 miles

Learn More »

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in advanced malignant mesothelioma patients.Furthermore,to characterize response to therapy,the investigators intent to explore the predictive biomarker for this regimen.

Phase

2.13 miles

Learn More »

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.Furthermore,to characterize response to therapy we intent to evaluate the role of cell-free DNA (cfDNA) and ...

Phase

2.13 miles

Learn More »

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.

Phase

2.13 miles

Learn More »

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.

Phase

2.27 miles

Learn More »

Combination of Chemotherapy SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) will receive GVD (Gemcitabine, Vinorelbine and Doxorubicine) chemotherapy and PD-1 antibodySHR-1210 with or without low-dose Decitabine priming. The safety and feasibility of combined regimens will be evaluated in phase I study. The subsequent phase II study ...

Phase

2.27 miles

Learn More »

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to evaluate whether treatment with the study drug decitabine in combination with SHR-1210 is safe and feasible, is more effective than treatment with SHR-1210 alone,and reverse the resistance of Anti-PD-1 antibody in patients with HL.

Phase

2.27 miles

Learn More »

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

PRIMARY OBJECTIVES: I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD19/CD22 vector (referred to as tanCART-19/22 cells). II. Determine duration of in vivo survival of tanCART-19/22 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect ...

Phase

2.27 miles

Learn More »